BCIQ Profiles

Company Profile ReportTarget Profile Report

MimiVax reports Phase II data for glioblastoma immunotherapy

MimiVax LLC (Buffalo, N.Y.) reported interim data from a Phase II trial in 63 newly diagnosed glioblastoma patients showing that subcutaneous SurVaxM

Read the full 226 word article

How to gain access

Continue reading with a
two-week free trial.